AstraZeneca Pharma India share news and announcements
NSE: ASTRAZENBSE: 506820Pharmaceuticals & BiotechnologySmall Cap
Formerly Astra IDL
Last close ₹5,988.50down ₹112.50 (1.84%)BSE ₹5,988.15
Share price at the NSE close on 23 Oct 2026. Previous close ₹6,101.00.
52-week range of traded prices to 23 Oct 2026
₹5,640.00Low, 9 Oct 2026₹9,849.50High, 3 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹14,971 Cr333rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 11 Aug 2026
- 88.3
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 26 May 2026
- 17.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.60%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 11 Aug 2026
- 20.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- 24.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 26 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 7,11847.8% delivered
AstraZeneca Pharma India share news and announcements
671 announcements, routine notices left out, newest first. Page 12 of 14.
Jan 2014
8 Jan · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2013.
Dec 2013
Nov 2013
Oct 2013
9 Oct · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2013.
Aug 2013
21 Aug · Disclosure of Voting Pattern - Clause 35A
Jul 2013
23 Jul · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2013.
May 2013
24 May · Meeting
Company has fixed Book Closure from August 11, 2013 to August 20, 2013 for the purpose of Annual General Meeting of the Company to be held on August 20, 2013.22 May · Board meeting
Board of Directors of the Company at its meeting held on May 21, 2013 has transacted the following :(1) Recommendation of Dividend: In view of absence of profits for the year ended March 31, 2013, and to conserve resources for future growth, the Board has not recommended any dividend on equity shares for the Financial Year ended March 31, 2013.13 May · Board meeting
Inter alia, to consider and approve the Audited Financial Results of the Company, for the last quarter and financial year ended March 31, 2013.6 May · Board meeting
3 May · Board meeting
To consider the 'Strategy Plan' for the Company.3 May · Board meeting
Board of Directors of the Company at its meeting held on May 02, 2013, has noted the resignation of Mr. Luigi Felice La Corte, Director, with effect from April 15, 2013. Further, Mr. Justin Ooi has been appointed as a Director of the Company in the vacancy caused by the resignation of Mr. Luigi Felice La Corte. The Board of Directors has also approved the appointment of Mr. Sanjay Murdeshwar as an Additional Director and also as Managing Director of the Company for a period of 3 years with effect from May 02, 2013. The appointment of Mr. Sanjay Murdeshwar as Managing Director is subject to the approval of the Central Government under Part I of Schedule XIII to the Companies Act, 1956. In view of inadequacy of profits of the Company for the year ended March 31, 2013, the remuneration payable by the Company to the Managing Director has been approved by the Remuneration Committee of the Board at its meeting held after the conclusion of the Board Meeting, as well as the appointment and remuneration is subject to the approval of the shareholders of the Company at the ensuing Annual General Meeting in accordance with the applicable provisions of Schedule XIII to the said act.
Mar 2013
5 Mar · Updates
Company has on March 05, 2013 received by e-mail communication a scanned copy of the letter dated February 28, 2013 from the promoter shareholder of the Company i.e. AstraZeneca Pharmaceuticals AB Sweden ("Promoter") notifying the Company of its decision to reduce its shareholding in the Company in order to comply with the requirement of minimum public shareholding, as specified in Securities Contracts (Regulation) Rules, 1957 ("SCRR") subject to receipt of all necessary statutory and regulatory approvals, as may be required, appropriate market conditions and investor interest. The current shareholding of the Promoter in the Company is approx. 89.99%.
Feb 2013
Jan 2013
23 Jan · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the third quarter and nine months ended December 31, 2012.
Dec 2012
6 Dec · Board meeting
Board of Directors of the Company at its meeting held on December 06, 2012, inter alia, has approved the following : (1) Appointment of Mr. Narayan K. Seshadri as an Additional Director on the Board with immediate effect and he would be acting as an Independent Director; (2) The employment term of Mr. Jonathan Hunt, Interim COO & President of the Company, whose appointment had been intimated vide letter dated August 23, 2012 and was valid till December 31, 2012, has been extended till March 12, 2013.
Nov 2012
27 Nov · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in AstraZeneca Pharma India Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. AstraZeneca Pharma India Limited has vide its letter inter-alia stated,"We have no information/announcement(including impending announcement) which in the Company's opinion may have a bearing on the price and/or significant increase in the volume of Company's shares across exchanges."
Oct 2012
19 Oct · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2012.
Aug 2012
23 Aug · Updates
Mr. Anandh Balasundaram has resigned as Managing Director and member of the Board with effect from the close of business hours on August 31, 2012. Accordingly, he shall cease to be Managing Director and Member of the Board of the Company with effect from the close of business hours on August 31, 2012. His resignation has been accepted by the Board of Directors on August 23, 2012. The Company has, an interim measure, appointed Mr. Jonathan Hunt as Chief Operating Officer (COO) and President, for a period of four months commencing from September 01, 2012.
Jul 2012
26 Jul · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter ended June 30, 2012.19 Jul · Disclosure of Voting Pattern - Clause 35A
Jun 2012
19 Jun · Meeting
Annual General Meeting of the Company is scheduled to be held on July 18, 2012. The Share Transfer Books and Register of Members will remain closed from July 11, 2012 to July 18, 2012 (including both days) for the purpose of ascertaining Dividend entitlement. It is proposed to make the dividend payments on August 17, 2012.
May 2012
12 May · Board meeting
Board of Directors of the Company at its meeting held on May 11, 2012 has appointed Mr. Pawan Singhal as the Vice President - Legal & Secretarial of the Company, and designated him as the "Compliance Officer" of the Company.12 May · Dividend
Board of Directors of the Company at its meeting held on May 11, 2012 has recommended a dividend of Rs.3.50/- per Equity Share of face value of Rs.2/- each (175%) for the Financial Year ended March 31, 2012, subject to the approval of the shareholders at the ensuing Annual General Meeting.
Apr 2012
24 Apr · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter ended March 31, 2012.
Mar 2012
6 Mar · News Verification
News Verification : The media had reports that the parent company Astrazeneca UK is looking to delist AstraZeneca Pharma India Limited. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. AstraZeneca Pharma India Limited has vide its letter inter-alia stated, "Please be informed that the Company has received no communication what so ever from overseas Promoter shareholder namely Astrazeneca Pharamceuticals AB, Sweden on the subject of delisting of the shares of this Company."
Feb 2012
Jan 2012
24 Jan · Updates
Mr. Raghunath Rath, Company Secretary and Compliance Officer of the Company ceased to be so w.e.f. closure of business hour on January 04, 2012. The Company is in the process of recruiting suitable person in place of Mr. Raghunath Rath.13 Jan · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter ended December 31, 2011.
Dec 2011
Nov 2011
Oct 2011
12 Oct · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter and half year ended September 30, 2011.
Sep 2011
Aug 2011
9 Aug · Change in Company Secretary
At the meeting of the Board of Directors of the Company held on August 08, 2011: (1) Mr. N. R. Srinivasan resigned from the position of VP-Legal & Company Secretary of the Company effective end of working hours of July 31, 2011. Consequently he will no more be the Compliance officer of the Company effective August 01, 2011.(2) Consequent to the above Mr. Raghunath Rath, Legal & Secretarial Manager, be and is hereby appointed as the officiating Company Secretary & Compliance Officer of the Company effective from August 08 , 2011.
Jul 2011